Medtronic PLC $MDT Holdings Raised by Corient Private Wealth LLC

Corient Private Wealth LLC lifted its stake in Medtronic PLC (NYSE:MDT) by 56.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 959,017 shares of the medical technology company’s stock after purchasing an additional 347,435 shares during the quarter. Corient Private Wealth LLC’s holdings in Medtronic were worth $83,598,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1248 Management LLC acquired a new position in shares of Medtronic in the first quarter worth about $26,000. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic in the 2nd quarter valued at approximately $27,000. Twin Tree Management LP acquired a new position in Medtronic in the 1st quarter worth approximately $29,000. Activest Wealth Management grew its position in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares in the last quarter. Finally, GFG Capital LLC acquired a new stake in Medtronic during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on MDT shares. Wells Fargo & Company raised their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Cowen reissued a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medtronic in a research note on Monday, December 8th. Daiwa Capital Markets upped their target price on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Finally, JPMorgan Chase & Co. raised their price target on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.44.

Medtronic Stock Performance

Shares of MDT stock opened at $98.68 on Tuesday. Medtronic PLC has a fifty-two week low of $79.29 and a fifty-two week high of $106.33. The stock’s 50-day moving average is $97.28 and its two-hundred day moving average is $93.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market cap of $126.51 billion, a P/E ratio of 26.60, a PEG ratio of 2.63 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the company earned $1.26 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.